ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2184

Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE

Simran Heera1, Matthew Sholdice2, Tania Cellucci3, Stephanie Garner4, Liane Heale5, Mark Matsos6, KAREN BEATTIE7 and Michelle Batthish3, 1McMaster University, Mississauga, ON, Canada, 2McMaster University, London, ON, Canada, 3McMaster Children's Hospital, Hamilton, ON, Canada, 4University of Calgary, Calgary, AB, Canada, 5McMaster University, Oakville, ON, Canada, 6McMaster Lupus Clinic, Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada, 7McMaster University, Hamilton, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Juvenile idiopathic arthritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: In Canada, adolescents with JIA and jSLE transfer from pediatric to adult care around age 18. This vulnerable transition period is associated with an increased risk of poor symptom and disease control, morbidity, and even mortality. These risks necessitate efforts be made to minimize the potential of loss to follow-up (LFU) at the time of transfer. Despite significant advances in research and models of transition to adult care, there has been a dearth of LFU data worldwide since the reporting of LFU rates (50%) from one Canadian centre in 2010. Despite identified challenges in determining LFU rates, we aimed to i) determine LFU rates of patients seen in a multidisciplinary transition program after transfer to adult care, and ii) describe characteristics of patients who were and were not LFU.

Methods: We performed a retrospective review of patients diagnosed with JIA or jSLE followed in the McMaster Children’s Hospital multidisciplinary rheumatology transition clinic and enrolled in a prospective, observational transition study. The clinic is staffed by pediatric and adult rheumatologists, nurses, an Advanced Physiotherapist Practitioner (APP), and a Child Life Specialist. Patients who did not attend their first or attended their first but not their second adult appointment were considered LFU. Patients seen at least twice in adult rheumatology or discharged after their first appointment were considered successful transfers. Patient demographics, disease characteristics (cJADAS 0-30, CHAQ 0-3, QoL 0-100, and pain 0-10) and transition readiness (Transition-Q, max 100) scores were recorded. Continuous variables were described using means and standard deviations, and categorical variables using frequencies and proportions. Differences in disease characteristics and Transition-Q scores were analyzed using unpaired t-tests.

Results: Ninety-six participants (n=65 female, 31 male) were included, of whom 71% successfully transferred to adult care (71% female) and 29% were LFU (61% female) (Figure 1). Patients took, on average, 21.3 months (12.4 SD) to successfully transfer from their last Transition Clinic appointment to their second adult rheumatology visit. Of those LFU, 93% never saw their adult rheumatologist. Those who were LFU had lower disease activity and pain scores, greater quality of life scores, and similar Transition-Q scores than those who were not LFU but the differences in disease characteristics and transition readiness were not statistically signfiicant (Table 1).

Conclusion: Integrating coordinated transfer of care processes from a multidisciplinary pediatric transition clinic resulted in lower LFU rates (29%) than previously reported (50%). Improved LFU rates may lead to improved long-term outcomes of patients with JIA or jSLE. While incomplete clinical data limited our results, those who were LFU appeared to be doing well compared to those who were not. However, differences in disease characteristics and Transition-Q scores were not significantly different between those who were and were not LFU. Future analyses will explore potential LFU predictors (e.g., disease status, parental involvement) and determine the impact of a transition coach intervention on rates of LFU.

Supporting image 1

Number of participants who were lost to follow up.

Supporting image 2

Patient demographics and characteristics.


Disclosures: S. Heera: None; M. Sholdice: None; T. Cellucci: None; S. Garner: None; L. Heale: Novartis, 5; M. Matsos: AbbVie/Abbott, 6, AstraZeneca, 6, GlaxoSmithKlein(GSK), 6; K. BEATTIE: None; M. Batthish: Abbvie, 6, Novartis, 2, Viatris, 12, Unrestricted Educational Grant.

To cite this abstract in AMA style:

Heera S, Sholdice M, Cellucci T, Garner S, Heale L, Matsos M, BEATTIE K, Batthish M. Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/loss-to-follow-up-after-transfer-from-pediatric-to-adult-care-in-patients-with-jia-or-jsle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/loss-to-follow-up-after-transfer-from-pediatric-to-adult-care-in-patients-with-jia-or-jsle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology